Tang Xiaojing, Voskoboev Nikolay V, Wannarka Stacie L, Olson Julie B, Milliner Dawn S, Lieske John C
Nephrology and Hypertension Research, Mayo Clinic, Rochester, Minn., USA.
Am J Nephrol. 2014;39(5):376-82. doi: 10.1159/000360624. Epub 2014 Apr 26.
Patients with primary hyperoxaluria (PH) overproduce oxalate which is eliminated via the kidneys. If end-stage kidney disease develops they are at high risk for systemic oxalosis, unless adequate oxalate is removed during hemodialysis (HD) to equal or exceed ongoing oxalate production. The purpose of this study was to validate a method to measure oxalate removal in this unique group of dialysis patients.
Fourteen stable patients with a confirmed diagnosis of PH on HD were included in the study. Oxalate was measured serially in hemodialysate and plasma samples in order to calculate rates of oxalate removal. HD regimens were adjusted according to a given patient's historical oxalate production, amount of oxalate removal at dialysis, residual renal clearance of oxalate, and plasma oxalate levels.
After a typical session of HD, plasma oxalate was reduced by 78.4 ± 7.7%. Eight patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. Combined oxalate removal by HD and the kidneys was sufficient to match or exceed endogenous oxalate production. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02).
This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
原发性高草酸尿症(PH)患者草酸盐产生过多,通过肾脏排出。如果发展为终末期肾病,他们发生全身性草酸中毒的风险很高,除非在血液透析(HD)期间清除足够的草酸盐以等于或超过持续的草酸盐产生量。本研究的目的是验证一种测量这一独特透析患者群体草酸盐清除率的方法。
14例确诊为HD的PH稳定患者纳入研究。连续测量血液透析液和血浆样本中的草酸盐,以计算草酸盐清除率。根据给定患者既往的草酸盐产生量、透析时的草酸盐清除量、草酸盐的残余肾清除率和血浆草酸盐水平调整HD方案。
经过一次典型的HD治疗后,血浆草酸盐降低了78.4±7.7%。8例患者每周进行6次HD,2例患者每周进行5次,3例患者每周进行3次。HD和肾脏联合清除草酸盐足以匹配或超过内源性草酸盐产生量。经过9个月的中位期后,透析前血浆草酸盐显著低于初始水平(75.1±33.4 vs.54.8±46.6 mmol/l,p = 0.02)。
该方法可用于个体化PH患者的透析处方,以防止在HD维持期间发生草酸中毒,并降低移植肾草酸盐损伤的风险。